CG Oncology

CGONNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$6.624 B

$75.10 +0.33%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$161.0M

Loss-making

Shares outstanding

88,640,375

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#19ImmunityBioIBRX$8.10B
#20Twist BioscienceTWST$7.25B
#21CG OncologyCGON$6.62B
#22Scholar RockSRRK$6.34B
#23CRISPR TherapeuticsCRSP$5.17B

Where these numbers come from

Share counts and financials for CG Oncology are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.